Abstract
Pepsinogen I (PGI) can reflect the morphology and function of the gastric mucosa. Accordingly, the large-scale community health screening of PGI can dramatically increase the early diagnosis rate of gastric cancer. However, PGI testing can only be carried out in comprehensive hospitals and health examination centers. To ameliorate this issue, a point-of-care chemiluminescent immunoassay for PGI was developed in a fully automated miniaturized instrument. This instrument was especially developed for health check-ups in the grassroots communities; its volume of which is only 0.18 m3. Critically, the entire detection process for a single sample only requires 20 min, and the samples can be loaded continuously, making the method suitable for high-throughput analysis. The assay displayed an excellent detection limit of 0.048 ng/mL with a broad detection range of 0–200 ng/mL. Furthermore, this assay exhibited high sensitivity and specificity, had low intra- and inter-assay coefficients of variation (<10%), and was not affected after storage at 37 °C for 7 days. The assay was used to detect PGI in 95 clinical serum samples, and the results were highly correlated with those that were clinically tested (correlation coefficient, R2 = 0.998). Hence, the method established in this work has great application value and can be broadly applied for the large-scale screening of gastric cancer in resource-limited areas.
Graphical abstract




Similar content being viewed by others
Change history
09 July 2021
A Correction to this paper has been published: https://doi.org/10.1007/s00216-021-03483-5
References
Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30:12–23.
Parn M-L, Innos K, Baburin A, Kiivet R-A, Jaal J. Gastric cancer trends in Estonia 1995-2014 by age, subsite, morphology and stage. Acta Oncol. 2019;58(3):283–9.
Wang K, Liang Q, Li X, Tsoi H, Yu J. MDGA2 is a novel tumour suppressor cooperating with DMAP1 in gastric cancer and is associated with disease outcome. Gut. 2015;65(10):1619–31.
Wang Y, Zhu Z, Liu Z, Zhao Z, Xue X, Li X, et al. Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer. J Int Med Res. 2020;48(3).
Mario FD, Cavallaro LG. Non-invasive tests in gastric diseases. Dig Liver Dis. 2008;40(7):523–30.
Nardone G, Rocco A, Staibano S, Mezza E, Autiero G, Compare D, et al. Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment Pharmacol Ther. 2005;22(11–12):1139–46.
Cha JH, Jang JS. Clinical correlation between serum pepsinogen level and gastric atrophy in gastric neoplasm. Korean J Intern Med. 2020;35(3):550–8.
Cao Q, Ran ZH, Xiao SD. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis. 2007;8(1):15–22.
Huang SC, Miki K, Hirano K, Hayashi Y, Furihata C, Shimizu A, et al. Enzyme-linked immunosorbent assay of serum pepsinogen I. Clin Chim Acta. 1987;162(1):85–96.
Banga-Mboko H, Sulon J, Closset J, Remy B, Youssao I, Sousa NMD, et al. An improved radioimmunoassay for measurement of pepsinogen in porcine blood samples. Vet J. 2003;165(3):288–95.
Huang B, Xiao H, Zhang X, Zhu L, Liu H, Jin J. Ultrasensitive detection of pepsinogen I and pepsinogen II by a time-resolved fluoroimmunoassay and its preliminary clinical applications. Anal Chim Acta. 2006;571(1):74–8.
Ogasawara D, Hirano Y, Yasukawa T, Shiku H, Kobori K, Ushizawa K, et al. Electrochemical microdevice with separable electrode and antibody chips for simultaneous detection of pepsinogens 1 and 2. Biosens Bioelectron. 2006;21(9):1784–90.
Cho EJ, Kim HK, Jeong TD, Ko DH, Min WK. Method evaluation of pepsinogen I/II assay based on chemiluminescent immunoassays and comparison with other test methods. Clin Chim Acta. 2015;452:149–54.
Nayak S, Blumenfeld NR, Laksanasopin T, Sia SK. Point-of-care diagnostics: recent developments in a connected age. Anal Chem. 2016;89(1):102–23.
Wang Y, Dzakah EE, Kang Y, Cai Y, Wu P, Tang B, et al. A sensitive and rapid chemiluminescence immunoassay for point-of-care testing (POCT) of copeptin in serum based on high-affinity monoclonal antibodies via cytokine-assisted immunization. Int J Nanomedicine. 2019;14:4293–307.
Qu Z, Wang K, Alfranca G, Fuente JM, Cui D. A plasmonic thermal sensing based portable device for lateral flow assay detection and quantification. Nanoscale Res Lett. 2020;15(1):10.
Poschenrieder A, Thaler M, Junker R, Luppa PB. Recent advances in immunodiagnostics based on biosensor technologies—from central laboratory to the point of care. Anal Bioanal Chem. 2019;411(7):7607–21.
Song M, Camargo MC, Weinstein SJ, Murphy G, Freedman ND, Koshiol J, et al. Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males. Aliment Pharmacol Ther. 2018;47(4):494–503.
Liu R, Wang C, Jiang Q, Zhang W, Liu G. Magnetic-particle-based, ultrasensitive chemiluminescence enzyme immunoassay for free prostate-specific antigen. Anal Chim Acta. 2013;801(4):91–6.
Fu X, Liu Y, Qiu R, Foda MF, Zhang Y, Wang T, et al. The fabrication of magnetic particle-based chemiluminescence immunoassay for human epididymis protein-4 detection in ovarian cancer. BB Reports. 2018;13:73–7.
Lin Z, Wang X, Li ZJ, Ren SQ, Chen GN, Ying XT, et al. Development of a sensitive, rapid, biotin-streptavidin based chemiluminescent enzyme immunoassay for human thyroid stimulating hormone. Talanta. 2008;75(4):965–72.
Rodriguez-Orozco AR, Ruiz-Reyes H, Medina-Serriteno N. Recent applications of chemiluminescence assays in clinical immunology. Mini-Rev Med Chem. 2010;10(14):1393–400.
Li Y, Ji X, Liu B. Chemiluminescence aptasensor for cocaine based on double-functionalized gold nanoprobes and functionalized magnetic microbeads. Anal Bioanal Chem. 2011;401(1):213–9.
Tudorache M, Zdrojewska IA, Emnéus J. Evaluation of progesterone content in saliva using magnetic particle-based immuno supported liquid membrane assay (m-ISLMA). Biosens Bioelectron. 2007;22(2):241–6.
Dungchai W, Siangproh W, Lin JM, Chailapakul O, Lin S, Ying X. Development of a sensitive micro-magnetic chemiluminescence enzyme immunoassay for the determination of carcinoembryonic antigen. Anal Bioanal Chem. 2007;387(6):1965–71.
Wang Y, Dzakah EE, Kang Y, Cai Y, Wu P, Cui Y, et al. Development of anti-Mullerian hormone immunoassay based on biolayer interferometry technology. Anal Bioanal Chem. 2019;411(21):5499–507.
Luxton R, Badesha J, Kiely J, Hawkins P. Use of external magnetic fields to reduce reaction times in an immunoassay using micrometer-sized paramagnetic particles as labels (magnetoimmunoassay). Anal Chem. 2004;76(6):1715–9.
Zhu D, Tang Y, Xing D, Chen WR. PCR-free quantitative detection of genetically modified organism from raw materials. An electrochemiluminescence-based bio bar code method. Anal Chem. 2008;80(10):3566–71.
Jie M, Yu S, Yu F, Liu L, He L, Li Y, et al. An ultrasensitive chemiluminescence immunoassay for fumonisin B-1 detection in cereals based on gold-coated magnetic nanoparticles. J Sci Food Agric. 2018;98(9):3384–90.
Gillet P, Mori M, Van Esbroeck M, Van den Ende J, Jacobs J. Assessment of the prozone effect in malaria rapid diagnostic tests. Malar J. 2009;8:271.
Singh S, Mishra P, Banga I. A SP, Prakash TP, Gandhi S. Chemiluminescence based immunoassay for the detection of heroin and its metabolites. Bioimpacts. 2018;8(1):53–8.
Chen, Zong, Duoduo, Zhang, Fan, Jiang, et al. Metal-enhanced chemiluminescence detection of C-reaction protein based on silver nanoparticle hybrid probes. Talanta. 2019;199:164–9.
Chang Y, Xu J, Zhang Q. Microplate magnetic chemiluminescence immunoassay for detecting urinary survivin in bladder cancer. Oncol Lett. 2017;14(4):4043–52.
Feng X-L, Ren H-L, Li Y-S, Hu P, Zhou Y, Liu Z-S, et al. A magnetic particles-based chemiluminescence enzyme immunoassay for rapid detection of ovalbumin. Anal Biochem. 2014;459:12–7.
Jiang W, Sun G, Zhang Y, Hu Z, Wen X, Men S, et al. Simultaneous determination of gastric cancer biomarkers pepsinogen PGI/PGII using element tagged immunoassay coupled with inductively coupled plasma mass spectrometry detection. J Clin Lab Anal. 2020;34(7):e23287.
Khramtsov P, Barkina I, Kropaneva M, Bochkova M, Timganova V, Nechaev A, et al. Magnetic nanoclusters coated with albumin, casein, and gelatin: size tuning, relaxivity, stability, protein corona, and application in nuclear magnetic resonance immunoassay. Nanomaterials. 2019;9(9):1345.
Crowther JR. The ELISA guidebook. Methods in molecular biology (Clifton, NJ). 2000;149:III-IV, 1–413.
Yang HJ, Bever CS, Zhang HY, Mari GM, Li HF, Zhang XY, et al. Comparison of soybean peroxidase with horseradish peroxidase and alkaline phosphatase used in immunoassays. Anal Biochem. 2019;581:9.
Funding
This work was supported by the Science and Technology Program of Guangdong Province (2021B1212050016), the Postdoctoral Scientific Research Project of Guangzhou (BHSKY20200301), the R & D Project in key areas of Guangdong Province (2020B1111160004), and Guangzhou Science and Technology Program (201902010003, 201802010030).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Ethics approval
The clinical serum and plasma samples were approved by the Research Ethics Committee of Third Affiliated Hospital of Guangzhou University of Chinese Medicine (AF/SC-08/02.0), and the study was performed in accordance with the relevant guidelines.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
"The original online version of this article was revised: The last name of the coauthor (Jingjing Zhou) has been wrongly written, which should be ‘Zou’ instead of ‘Zhou’." plus the same explanatory text of the problem as in the erratum/correction article
Supplementary information
ESM 1
(PDF 523 kb)
Rights and permissions
About this article
Cite this article
Liu, F., Zou, J., Luo, X. et al. A point-of-care chemiluminescence immunoassay for pepsinogen I enables large-scale community health screening. Anal Bioanal Chem 413, 4493–4500 (2021). https://doi.org/10.1007/s00216-021-03412-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-021-03412-6